middle.news
Paradigm Biopharma Taps Advanced Clinical for Pivotal Phase 3 Osteoarthritis Trial
6:38pm on Sunday 1st of June, 2025 AEST
•
Biotechnology
Read Story
Paradigm Biopharma Taps Advanced Clinical for Pivotal Phase 3 Osteoarthritis Trial
6:38pm on Sunday 1st of June, 2025 AEST
Key Points
Advanced Clinical selected as preferred CRO for PARA_OA_012 Phase 3 trial
Trial to enrol approximately 466 participants with knee osteoarthritis pain
First participant dosing targeted for Q2 calendar year 2025
Advanced Clinical brings global reach and osteoarthritis expertise
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Paradigm Biopharmaceuticals (ASX:PAR)
OPEN ARTICLE